RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers. However, this goal has been elusive because of the absence of any drug-binding ...
Apr 21, 2016
In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular ...
Apr 21, 2016
New data analyses found no association between anthracycline chemotherapy and greater risk of cognitive decline in breast cancer survivors, according to an article published online by JAMA Oncology.
Apr 21, 2016
